Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.
about
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group.Drug treatment of functional dyspepsia.Approaches to uninvestigated dyspepsia.Dyspepsia: management guidelines for the millennium.Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.Evaluation and treatment of dyspepsia.Review article: management of mild and severe gastro-oesophageal reflux disease.Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy.The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies.Proton pump inhibitors for functional dyspepsia.Association of symptoms of gastroesophageal reflux with metabolic syndrome parameters in patients with endocrine disease.Therapeutic strategies for the treatment of dyspepsia.Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia.Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.ACG and CAG Clinical Guideline: Management of Dyspepsia.Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care.Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial.Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia.High prevalence of gastroesophageal reflux disease in Parkinson's disease: a questionnaire-based study.A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias.Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia.Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial.Management of uninvestigated and functional dyspepsia: a working party report for the World Congresses of Gastroenterology 1998
P2860
Q33952311-4A1BB3A0-CFDC-497D-BE8B-0575CA04C4E9Q34529448-37B62C4F-A991-44DE-AA53-7ACA828648FFQ34601058-C56263F2-349F-416D-B89D-2BABBF2A4AB7Q34601100-5039AEAD-1C10-4CC9-ABED-F65105BB51B7Q34755597-EB8574C8-24FD-4A51-9272-DBFD7B1F5C41Q35017527-62BEE7F8-ED85-4850-8428-62AD07FAF236Q35059333-CC0B2158-8859-411B-A431-8773F22CA36CQ35145033-9E57A0F5-7B7B-46B4-BB21-2AD5910AE068Q35595066-A58A2CE4-072A-4E74-8FC0-DBCC11EC9BC0Q35630044-694698FE-B8D3-4705-B09E-9BBC205C8E46Q35790399-DBC5D7BF-3457-4C62-B42B-3C7E494742A9Q36300366-CF66E97E-DD10-4C33-BF1E-8252A706A542Q37593148-53E340E8-BF66-4B81-B45B-44D470CFA1CEQ37781371-9BD6582F-BD81-4F9B-B67F-3E817EC7459FQ38240885-03002828-B17C-455C-BF43-376E8530123CQ39367299-BAFC75A2-86B5-43AF-81AD-5A5D269430D2Q39385451-C6641744-65B2-4DEF-955F-DC37534A4B86Q39412700-2ADE8E34-427E-406C-8F57-E53DDF918BD7Q39413392-AABE9279-1619-44AA-9250-9A202ED85B88Q39417568-FBFA6F77-8850-4CD5-8961-14945C1B42D7Q39423996-1F2B7634-DD31-49CE-9EE4-B8D82C630734Q39438220-8C7B9667-3490-4335-AA1A-E1BD7F9E002BQ39440435-08224BF2-28EA-4B13-B402-17BD9CE10F18Q43239160-559C61E3-6FF2-4E84-B082-DFF64C8644CCQ44903078-BB0DB4DB-7B41-46FA-9319-4D2C5F59E4B9Q45009908-D85644CE-4F44-4E3B-83E2-66D62674F52DQ47670014-8240775A-EAE9-4C93-A908-1F4C7CD2DE0CQ52240962-DA93ECBD-FC9A-4EC1-B7E0-92A66BC095CCQ52946073-22883D25-C82B-4CA3-B57D-7CE8060D5B4EQ57789860-0649ED39-4524-41CA-9120-7CC1DBC74A25
P2860
Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@en
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@nl
type
label
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@en
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@nl
prefLabel
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@en
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@nl
P1476
Lansoprazole 30 mg daily versu ...... dyspepsia in general practice.
@en
P2093
P304
P356
10.1046/J.1365-2036.1997.00179.X
P407
P577
1997-06-01T00:00:00Z